Arvinas Inc (NASDAQ: ARVN) disclosed that it has received authorization to proceed for its IND application for PROTAC therapy to treat patients with metastatic castration-resistant prostate cancer.
The announcement came down Monday that the U.S. Food and Drug Administration(FDA) has cleared the company’s investigational new drug application (IND) for ARV-110, an oral androgen receptor (AR) PROTAC™ protein degrader, for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).
Arvinas expects to begin enrollment of a Phase 1 clinical trial for ARV-110 in the first quarter of this year.
According to CEO John Houston, “This IND clearance is a key step forward for Arvinasand for the field of protein degradation
“Our PROTAC platform has demonstrated exciting promise in preclinical studies and represents an entirely new approach to treating patients with mCRPC and many other diseases. We hope ARV-110 will deliver a much-needed new therapeutic option for patients, and we expect to dose our first patient in the first quarter of 2019.”
ARV-110 was developed using Arvinas’ proprietary technology platform – PROTAC (proteolysis-targeting chimera) protein degraders – that uses small molecules to harness the body’s own natural protein recycling system (the ubiquitin proteasome system) to selectively and efficiently remove disease-causing proteins.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.